Astaxanthin extract pharma grade API is supplied as a microcrystalline, solvent-free carotenoid powder derived from Haematococcus pluvialis biomass by supercritical CO₂ extraction followed by controlled saponification to convert naturally esterified astaxanthin into free 3S,3'S-astaxanthin. The oral solid-dose model, designated ASX-PH-OSD, is sieved to a particle-size distribution with D₉₀ ≤ 45 µm and is intended for tablet, capsule, and granule manufacture. The injectable model, designated ASX-PH-PI, is processed to low endotoxin and low bioburden limits, with D₉₀ ≤ 10 µm to support aseptic compounding and liposomal or lipid-emulsion loading. The molecule has molecular formula C₄₀H₅₂O₄ and molecular mass 596.84 g/mol. Because aqueous solubility at pH 7.4 is below 0.01 mg/mL, oral solid formulations typically employ the API in a lipid or surfactant-containing matrix, while injectable formulations require phospholipid complexes, micellar systems, or oil-in-water emulsions. The product differs from Haematococcus oleoresin by removing neutral lipids, chlorophylls, and esterified carotenoids to yield a free astaxanthin assay of not less than 97.0% when tested by HPLC, and from synthetic astaxanthin by preserving the natural 3S,3'S stereoisomer profile rather than a defined racemic mixture.

A Release Specification Framework for Oral and Parenteral Grades

Two separate specification sets are applied because injectable manufacture introduces pyrogen, particulate, and sterile-processing limits that do not apply to oral solid-dose APIs. Table 1 summarizes representative release parameters for the two grades. The analytical methods follow ICH Q2(R1) validation requirements, with HPLC detection at 474 nm using a C30 carotenoid column to resolve all-trans astaxanthin from 9-cis and 13-cis isomers. Residual solvents are controlled according to ICH Q3C; elemental impurities are managed under ICH Q3D with oral and parenteral permitted daily exposure limits. Microbiological acceptance criteria follow Ph. Eur. 2.6.12 and 2.6.13 and USP <61> and <62>. The processing windows and acceptance limits in this section are manufacturer specifications for the API; independent published data for every formulation configuration is limited. Formulators should qualify the API in the finished product under ICH Q1A(R2) stability conditions because carotenoid degradation is matrix-dependent.

The injectable grade is not a terminal sterile product; it is an aseptic-processing input. If terminal sterilization by autoclave is applied to a simple aqueous suspension, unprotected astaxanthin is known to degrade at temperatures above 70 °C, and terminal steam sterilization at 121 °C is therefore not specified for aqueous formulations. The manufacturer specifies that the injectable grade be compounded into oxygen-purged lipid or liposomal carriers before filtration. The oral solid-dose grade is tested for residual solvents against ICH Q3C class 2 and class 3 limits, including ethanol and ethyl acetate from extraction and saponification steps, with ethanol not more than 5000 ppm and ethyl acetate not more than 5000 ppm in typical specification.

What Limits Direct Compression and Aqueous Granulation of Carotenoid APIs?

Direct compression of the oral solid-dose grade is constrained by low bulk density, typically 0.25–0.45 g/mL, and by electrostatic adhesion to stainless steel contact surfaces. Manufacturing guidance specifies a pre-blend step in a bin blender at 15–20 rpm for 10–15 min after the API is deagglomerated through a 0.5 mm sieve. Blends containing 2.0–5.0 wt% API with microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate are compressed on a rotary tablet press to a tablet hardness of 70–90 N and a friability below 1.0% when tested according to USP <1216>. Lubricant level is specified at not more than 1.5 wt% because higher magnesium stearate levels can prolong disintegration by forming hydrophobic lubricant domains that interact with the lipophilic carotenoid.

Aqueous wet granulation is applicable only with an oxygen-protective binder system. The specified granulating fluid is a 5.0% w/v hypromellose solution containing 0.5% w/w ascorbyl palmitate. A high-shear granulator fitted with nitrogen purging is operated at impeller speed 150–250 rpm and chopper speed 1500–2500 rpm. Wet mass is dried in a fluidized-bed dryer with inlet air temperature maintained at 45–50 °C until loss on drying reaches 2.0–2.5%. Drying above 55 °C is not specified because the molecule is thermolabile and oxygen-sensitive; tray drying is also not recommended because extended residence time in an oxygen-containing atmosphere increases cis-isomerization.

For moisture-sensitive matrices or extended-release formulations, dry granulation by roller compaction is preferred. Ribbon density is controlled between 0.90 and 1.10 g/cm³ with roll force 8–12 kN/cm and screen milling through a 1.0 mm mesh. Capsule filling on an automatic dosator machine with a line speed of 50,000 capsules/h requires the granulate to maintain a Carr index below 25% and an angle of repose below 35°. Hard gelatin capsules in desiccant-loaded HDPE bottles provide better photostability than uncolored PVC blister packs because astaxanthin is highly sensitive to light and oxygen.

Film coating of astaxanthin-containing tablets is specified with a non-aqueous or hydroalcoholic hydroxypropyl methylcellulose system at a pan inlet temperature of 45–55 °C and atomization air pressure of 1.5–2.0 bar. Aqueous coating suspensions are acceptable only when the core has been sealed with a lipid barrier or when coating time is below 60 min, because prolonged moisture contact increases surface oxidation of the carotenoid. Tablets are therefore coated to a weight gain of 2.0–3.0% and packaged with oxygen scavengers.

Injection Grade Requirements Extend Beyond Assay and Impurity Limits

The injectable grade is controlled for chromatographic purity, bacterial endotoxins, bioburden, particulate matter, and compatibility with aseptic filtration. Because free astaxanthin is practically insoluble in water at pH 7.4, the specified pharmaceutical strategy is to dissolve the API in ethanol or polysorbate 80 and load it into pre-formed phospholipid liposomes or medium-chain triglyceride emulsions. During compounding, the API is added to the lipid phase and dissolved under nitrogen at 40–50 °C, followed by high-pressure homogenization at 800–1200 bar. Aseptic filtration of the finished lipid dispersion through a 0.22 µm membrane is feasible when mean droplet diameter is below 200 nm. Filling is performed under ISO 14644-1 class 5 conditions into amber borosilicate vials with nitrogen headspace.

Liposomal formulations require phospholipid-to-API molar ratios from 10:1 to 20:1 and cholesterol levels of 30–40 mol% to achieve a mean vesicle diameter below 200 nm. The lipid phase is prepared with hydrogenated phosphatidylcholine and cholesterol dissolved in ethanol at 60 °C, then mixed with aqueous buffer at 50 °C under high-shear mixing before homogenization. The API is protected from light throughout processing; the finished emulsion is purged with nitrogen until headspace oxygen is below 1.0%.

Terminal autoclaving of unprotected aqueous astaxanthin solutions is not a default option. The molecule degrades at temperatures above 70 °C, and published stability data for terminal sterilization of unprotected aqueous solutions indicate that degradation is significant; therefore, sterile filtration of liposomal or lipid dispersions or lyophilization of a sucrose-trehalose lyoprotected product is specified. The lyophilized cake is controlled for moisture not more than 1.0%, reconstitution time not more than 60 s, and liposome size after reconstitution not more than 200 nm. The reconstituted product should be used immediately after preparation because the API undergoes photo-oxidation in solution.

When Synthetic Astaxanthin Replaces Natural Free Astaxanthin in a Formulation

Natural free astaxanthin, natural Haematococcus oleoresin, and synthetic astaxanthin are not directly interchangeable. The natural free API contains predominantly the 3S,3'S stereoisomer; natural Haematococcus oleoresin is primarily esterified astaxanthin with a total astaxanthin content of 5–15% and variable amounts of triacylglycerols, phospholipids, and β-carotene. Synthetic astaxanthin is produced as a free stereoisomer mixture with a defined 1:2:1 ratio of (3R,3'R), (3R,3'S), and (3S,3'S) stereoisomers. These differences influence dissolution, partition coefficient, and antioxidant activity in in vitro assays. Table 2 provides the principal differentiating variables.

The natural free API is therefore selected when a high-purity, low-endotoxin carotenoid with a defined stereoisomer profile is required for oral solid-dose or injectable lipid-based products. Differences in esterification state affect purification burden: the oleoresin requires additional saponification and chromatographic steps to reach API-grade purity, while synthetic astaxanthin requires control of synthesis intermediates and residual solvents under ICH Q3C. Published data comparing the clinical antioxidant activity of the separate stereoisomers are limited, so the specification emphasizes stereochemical identity rather than assuming equivalence.

Handling and storage requirements apply at every transfer point. The API is stored in sealed, triple-laminated aluminum pouches under nitrogen at −20 °C to −8 °C, protected from light, and warmed to ambient temperature before opening to avoid moisture condensation. At relative humidity above 60%, opened containers absorb water and the powder becomes cohesive; if pre-drying is required, a vacuum dryer at 40 °C for 4–6 h under nitrogen is specified. Prolonged exposure to laboratory air is avoided because astaxanthin is oxidized by peroxy radicals and singlet oxygen; this reactivity is the basis of its antioxidant function but represents a stability risk when the molecule is isolated.